AC Immune (ACIU) Cash from Financing Activities (2015 - 2024)

AC Immune (ACIU) has 10 years of Cash from Financing Activities data on file, last reported at -$224879.8 in Q4 2024.

• On a quarterly basis, Cash from Financing Activities fell 100.49% year-over-year to -$224879.8 in Q4 2024; TTM through Dec 2024 was $46.3 million, a 0.26% change from a year earlier, with the FY2025 full-year figure at -$1.2 million, up 3.77% from the prior year.
• Cash from Financing Activities for Q4 2024 stood at -$224879.8, down from -$199677.9 in the prior quarter.
• Over the last five years, Cash from Financing Activities for ACIU reached as high as $46.3 million in Q4 2023 and fell as low as -$991852.5 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $5.5 million across 5 years, with a median of -$126646.0 in 2020.
• Across the five-year window, Cash from Financing Activities plunged 6195.03% in 2020 and jumped 29609.2% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at -$508831.6 in 2020, then jumped by 6224.03% to $31.2 million in 2021, then tumbled by 100.5% to -$156741.3 in 2022, then soared by 29609.2% to $46.3 million in 2023, then sank by 100.49% to -$224879.8 in 2024.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$224879.8 in Q4 2024, -$199677.9 in Q3 2024, and $46.3 million in Q4 2023.